Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.

Mills JR, Kohlhagen MC, Willrich MAV, Kourelis T, Dispenzieri A, Murray DL.

Blood. 2018 Jun 11. pii: blood-2018-05-848986. doi: 10.1182/blood-2018-05-848986. [Epub ahead of print] No abstract available.

PMID:
29891533
2.

The Complement Alternative Pathway and Preeclampsia.

Alrahmani L, Willrich MAV.

Curr Hypertens Rep. 2018 May 1;20(5):40. doi: 10.1007/s11906-018-0836-4. Review.

PMID:
29717384
3.

CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes.

Gurtner KM, Shosha E, Bryant SC, Andreguetto BD, Murray DL, Pittock SJ, Willrich MAV.

Clin Chem Lab Med. 2018 Jun 27;56(7):1071-1080. doi: 10.1515/cclm-2017-0901.

PMID:
29455184
4.

Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Willrich MAV, Murray DL, Kyle RA.

Clin Biochem. 2018 Jan;51:38-47. doi: 10.1016/j.clinbiochem.2017.05.001. Epub 2017 May 4. Review.

PMID:
28479151
5.

Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory.

Ladwig PM, Barnidge DR, Willrich MAV.

Clin Vaccine Immunol. 2017 May 5;24(5). pii: e00545-16. doi: 10.1128/CVI.00545-16. Print 2017 May. Review.

6.

Quantification of the IgG2/4 kappa Monoclonal Therapeutic Eculizumab from Serum Using Isotype Specific Affinity Purification and Microflow LC-ESI-Q-TOF Mass Spectrometry.

Ladwig PM, Barnidge DR, Willrich MA.

J Am Soc Mass Spectrom. 2017 May;28(5):811-817. doi: 10.1007/s13361-016-1566-y. Epub 2016 Dec 21.

PMID:
28004336
7.

Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation.

Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA.

Adv Clin Chem. 2016;77:1-75. doi: 10.1016/bs.acc.2016.06.001. Epub 2016 Jul 5. Review.

PMID:
27717414
8.

Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.

Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, Willrich MA, Barnidge DR, Dispenzieri A, Murray DL.

Clin Chem. 2016 Oct;62(10):1334-44. doi: 10.1373/clinchem.2015.253740. Epub 2016 Aug 18.

9.

Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.

Kohlhagen MC, Barnidge DR, Mills JR, Stoner J, Gurtner KM, Liptac AM, Lofgren DI, Vanderboom PM, Dispenzieri A, Katzmann JA, Willrich MA, Snyder MR, Murray DL.

Clin Chem. 2016 Oct;62(10):1345-52. doi: 10.1373/clinchem.2015.253781. Epub 2016 Aug 11.

10.

Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group.

Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, Amer H, Hogan WJ, Marshall AL, Sethi S, Tran CL, Chen D, Pruthi RK, Ashrani AA, Fervenza FC, Cramer CH 2nd, Rodriguez V, Wolanskyj AP, Thomé SD, Hook CC; Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group.

Mayo Clin Proc. 2016 Sep;91(9):1189-211. doi: 10.1016/j.mayocp.2016.05.015. Epub 2016 Aug 3.

PMID:
27497856
11.

Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis.

Mills JR, Cornec D, Dasari S, Ladwig PM, Hummel AM, Cheu M, Murray DL, Willrich MA, Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Stone JH, Specks U, Barnidge DR.

Anal Chem. 2016 Jun 21;88(12):6317-25. doi: 10.1021/acs.analchem.6b00544. Epub 2016 Jun 3.

12.

Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation.

Willrich MA, Ladwig PM, Andreguetto BD, Barnidge DR, Murray DL, Katzmann JA, Snyder MR.

Clin Chem Lab Med. 2016 Jun 1;54(6):1085-93. doi: 10.1515/cclm-2015-1023.

PMID:
26812875
13.

Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry.

Barnidge DR, Kohlhagen MC, Zheng S, Willrich MA, Katzmann JA, Pittock SJ, Murray DL.

J Neuroimmunol. 2015 Nov 15;288:123-6. doi: 10.1016/j.jneuroim.2015.09.011.

PMID:
26531705
14.

Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias.

Willrich MA, Katzmann JA.

Clin Chem Lab Med. 2016 Jun 1;54(6):907-19. doi: 10.1515/cclm-2015-0580. Review.

15.

Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS/MS.

Willrich MA, Murray DL, Barnidge DR, Ladwig PM, Snyder MR.

Int Immunopharmacol. 2015 Sep;28(1):513-20. doi: 10.1016/j.intimp.2015.07.007. Epub 2015 Jul 25.

PMID:
26210595
16.

A dark-brown serum sample.

Willrich MA, Wittwer CA, Baumann NA, Block DR.

Clin Chem. 2015 Jul;61(7):999-1000. doi: 10.1373/clinchem.2015.238493. No abstract available.

17.

Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.

Katzmann JA, Willrich MA, Kohlhagen MC, Kyle RA, Murray DL, Snyder MR, Rajkumar SV, Dispenzieri A.

Clin Chem. 2015 Feb;61(2):360-7. doi: 10.1373/clinchem.2014.231985. Epub 2014 Dec 1.

18.

Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases.

Willrich MA, Murray DL, Snyder MR.

Transl Res. 2015 Feb;165(2):270-82. doi: 10.1016/j.trsl.2014.09.006. Epub 2014 Sep 22. Review.

PMID:
25305470
19.

Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry.

Barnidge DR, Dasari S, Ramirez-Alvarado M, Fontan A, Willrich MA, Tschumper RC, Jelinek DF, Snyder MR, Dispenzieri A, Katzmann JA, Murray DL.

J Proteome Res. 2014 Nov 7;13(11):5198-205. doi: 10.1021/pr5005967. Epub 2014 Aug 26.

PMID:
25134970
20.

PCSK9 and the road less traveled: how an unconventional approach led to a major discovery.

Willrich MA, Baudhuin LM.

Clin Chem. 2013 Aug;59(8):1283-4. No abstract available.

21.

Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.

Willrich MA, Rodrigues AC, Cerda A, Genvigir FD, Arazi SS, Dorea EL, Bernik MM, Bertolami MC, Faludi A, Largura A, Baudhuin LM, Bryant SC, Hirata MH, Hirata RD.

Clin Chim Acta. 2013 Jun 5;421:157-63. doi: 10.1016/j.cca.2013.03.007. Epub 2013 Mar 15.

22.

Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response.

Rodrigues AC, Sobrino B, Genvigir FD, Willrich MA, Arazi SS, Dorea EL, Bernik MM, Bertolami M, Faludi AA, Brion MJ, Carracedo A, Hirata MH, Hirata RD.

Clin Chim Acta. 2013 Feb 18;417:8-11. doi: 10.1016/j.cca.2012.11.028. Epub 2012 Dec 13.

PMID:
23247049
23.

Differentiation of African components of ancestry to stratify groups in a case-control study of a Brazilian urban population.

Silbiger VN, Hirata MH, Luchessi AD, Genvigir FD, Cerda A, Rodrigues AC, Willrich MA, Arazi SS, Dorea EL, Bernik MM, Faludi AA, Bertolami MC, Santos C, Carracedo A, Salas A, Freire A, Lareu MV, Phillips C, Porras-Hurtado L, Fondevila M, Hirata RD.

Genet Test Mol Biomarkers. 2012 Jun;16(6):524-30. doi: 10.1089/gtmb.2011.0267. Epub 2012 Jan 30.

24.

Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.

Cerda A, Genvigir FD, Willrich MA, Arazi SS, Bernik MM, Dorea EL, Bertolami MC, Faludi AA, Hirata MH, Hirata RD.

Lipids Health Dis. 2011 Nov 10;10:206. doi: 10.1186/1476-511X-10-206.

25.

Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.

Rodrigues AC, Perin PM, Purim SG, Silbiger VN, Genvigir FD, Willrich MA, Arazi SS, Luchessi AD, Hirata MH, Bernik MM, Dorea EL, Santos C, Faludi AA, Bertolami MC, Salas A, Freire A, Lareu MV, Phillips C, Porras-Hurtado L, Fondevila M, Carracedo A, Hirata RD.

Int J Mol Sci. 2011;12(9):5815-27. doi: 10.3390/ijms12095815. Epub 2011 Sep 9.

26.

Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression.

Cerda Á, Genvigir FD, Rodrigues AC, Willrich MA, Dorea EL, Bernik MM, Arazi SS, Oliveira Rd, Hirata MH, Hirata RD.

J Atheroscler Thromb. 2011;18(8):640-51. Epub 2011 Apr 21.

27.

Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.

Genvigir FD, Rodrigues AC, Cerda A, Arazi SS, Willrich MA, Oliveira R, Hirata MH, Dorea EL, Bernik MM, Curi R, Hirata RD.

Pharmacogenomics. 2010 Sep;11(9):1235-46. doi: 10.2217/pgs.10.93.

PMID:
20860464
28.

Statin regulation of CYP3A4 and CYP3A5 expression.

Willrich MA, Hirata MH, Hirata RD.

Pharmacogenomics. 2009 Jun;10(6):1017-24. doi: 10.2217/pgs.09.42. Review.

PMID:
19530969
29.

ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment.

Rebecchi IM, Rodrigues AC, Arazi SS, Genvigir FD, Willrich MA, Hirata MH, Soares SA, Bertolami MC, Faludi AA, Bernik MM, Dorea EL, Dagli ML, Avanzo JL, Hirata RD.

Biochem Pharmacol. 2009 Jan 1;77(1):66-75. doi: 10.1016/j.bcp.2008.09.019. Epub 2008 Sep 21.

PMID:
18851956
30.

CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.

Willrich MA, Hirata MH, Genvigir FD, Arazi SS, Rebecchi IM, Rodrigues AC, Bernik MM, Dorea EL, Bertolami MC, Faludi AA, Hirata RD.

Clin Chim Acta. 2008 Dec;398(1-2):15-20. doi: 10.1016/j.cca.2008.07.032. Epub 2008 Aug 5.

PMID:
18727922
31.

Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response.

Arazi SS, Genvigir FD, Willrich MA, Hirata MH, Dorea EL, Bernik M, Hirata RD.

Clin Chim Acta. 2008 Jul 17;393(2):119-24. doi: 10.1016/j.cca.2008.03.031. Epub 2008 Apr 8.

PMID:
18435918
32.

Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals.

Genvigir FD, Soares SA, Hirata MH, Willrich MA, Arazi SS, Rebecchi IM, Oliveira R, Bernik MM, Dorea EL, Bertolami MC, Hirata RD.

Clin Chim Acta. 2008 Mar;389(1-2):79-86. doi: 10.1016/j.cca.2007.11.029. Epub 2007 Dec 7.

PMID:
18164264
33.

Acute effect of Bauhinia forficata on serum glucose levels in normal and alloxan-induced diabetic rats.

Silva FR, Szpoganicz B, Pizzolatti MG, Willrich MA, de Sousa E.

J Ethnopharmacol. 2002 Nov;83(1-2):33-7.

PMID:
12413705

Supplemental Content

Loading ...
Support Center